Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Niswander

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Haematologica|August 11, 2022
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute lymphoblastic leukemiaLisa M Niswander, Zachary T Graff, Christopher D Chien, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct designHaiying Qin, Lila Yang, John A Chukinas, et al.
Leukemia|December 16, 2024
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemiaTommaso Balestra, Lisa M Niswander, Asen Bagashev, et al.
Haematologica|July 1, 2021
Therapeutic potential of ruxolitinib and ponatinib in patients with <i>EPOR</i>-rearranged Philadelphia chromosome-like acute lymphoblastic leukemiaLisa M Niswander, Joseph P Loftus, Élodie Lainey, et al.
Plos Genetics|September 6, 2007
Mutation in mouse hei10, an e3 ubiquitin ligase, disrupts meiotic crossing overJeremy O Ward, Laura G Reinholdt, William W Motley, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Haematologica|August 11, 2022
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute lymphoblastic leukemiaLisa M Niswander, Zachary T Graff, Christopher D Chien, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct designHaiying Qin, Lila Yang, John A Chukinas, et al.
Leukemia|December 16, 2024
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemiaTommaso Balestra, Lisa M Niswander, Asen Bagashev, et al.
Haematologica|July 1, 2021
Therapeutic potential of ruxolitinib and ponatinib in patients with <i>EPOR</i>-rearranged Philadelphia chromosome-like acute lymphoblastic leukemiaLisa M Niswander, Joseph P Loftus, Élodie Lainey, et al.
Plos Genetics|September 6, 2007
Mutation in mouse hei10, an e3 ubiquitin ligase, disrupts meiotic crossing overJeremy O Ward, Laura G Reinholdt, William W Motley, et al.
Pageof 2